Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine

Pharmacogenetics

Volumn 9, Issue 5, 1999, Pages 657-660

  Bernal, Maria Luisa ^a,b   Sinues, Blanca ^a   Johansson, Inger ^c   McLellan, Roman A ^c   Wennerholm, Agneta ^b,c   Dahl, Marja Liisa ^b   Ingelman Sundberg, Magnus ^c   Bertilsson, Leif ^b  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Debrisoquine; Gene amplification; Gene duplication; Ultrarapid metabolism

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE AMPLIFICATION; GENE DUPLICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SPAIN;

EID: 0032718495     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199910000-00013     Document Type: Article

References (22)

1. Agúndez JAG, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 1994; 55:412-417.
2. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57:265-269.
3. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodriguez F, Ingelman- Sundberg I. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278:441-446.
4. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP206 in a European population. DNA Cell Biol 1991; 8:545-558.
5. Bertilsson L, Dahl ML. Polymorphic drug oxidation; relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5:200-223.
6. Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine - a case report with implication for treatment with nortriptyline and other tricyclic anti- depressants. Ther Drug Monit 1985; 7:478-480.
7. Bertilsson L, Dahl ML, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341:63.
8. Cavalli-Sforza LL, Menozzi P, Piazza A. The history and geography of human genes. Princeton, NJ: Princeton University Press; 1996.
9. Dahl ML, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51:12-17.
10. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274:516-520.
11. Dalén P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10- Hydroxylation of nortriptyline in Caucasians with 0, 1, 2, 3 and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63:444-452.
12. Heim MH, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 2: 529-532.
13. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90:11825-11829.
14. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. PCR- based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996; 6:351-355.
15. London SJ, Daly AK, Leathart JBS, Navidi WC, Carpenter CC, Idle JR. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis 1997; 18:1203-1214.
16. Lovlie R, Daly AK, Idle JR, Steen VM. Characterization of the 16 + 9 kb and 30 + 9 kb CYP2D6 XbaI haplotypes. Pharmacogenetics 1997; 7:149-152.
17. Lundqvist E. Pharmacogenetics of cytochrome P4502D6 - duplication and amplification of an active CYP2D6 gene as a cause of ultrarapid drug metabolism. MSc thesis; Karolinska Institute. Stockholm, Sweden; 1997.
18. McLellan RA, Oscarson M, Seidegård JE, Evans DAP, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7:187-191.
19. Neitzel HA. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986; 73; 320-332.
20. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
21. Sachse C, Brockmöller J, Hildebrannd, Müller K, Roots I. Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics 1998; 8:181-185.
22. Sanz EJ, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotype in a Swedish population - determined after co-administration with debrisoquine. Clin Pharmacol Ther 1989; 45:495-499.